CJC-1295 vs L-Carnitine (Injectable)
Side-by-Side Comparison
| Attribute | Cjc 1295 | L Carnitine Injectable |
|---|---|---|
| Category | Growth Hormone Secretagogue | Metabolic / Fat Oxidation |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | L-Carnitine binds long-chain fatty acyl-CoA molecules and shuttles them across the mitochondrial inner membrane via the carnitine palmitoyltransferase (CPT) system. |
| Evidence Rating | D — Preclinical | B — Meaningful Human Clinical Data |
| Clinical Status | Research-only / Not approved for human use | FDA-approved (IV, for carnitine deficiency). SC injection widely used off-label for metabolic optimization. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | Generally well tolerated; long safety record in approved IV formulations; SC injection site pain/burning (common with higher concentrations) |
| Route | Subcutaneous | Subcutaneous injection |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 50-200 mg per injection |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | Once daily |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~161.2 g/mol |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | ~2-4 hours (plasma) |
Overview
CJC-1295 and L-Carnitine (Injectable) are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
L-Carnitine (Injectable) — Mechanism & Evidence
Injectable L-Carnitine is a naturally occurring amino acid derivative (MW ~161.2 g/mol) that facilitates the transport of long-chain fatty acids across the mitochondrial inner membrane for beta-oxidation. While oral L-carnitine has poor bioavailability (5-18%), subcutaneous injection achieves near-100% bioavailability, making it a significantly more effective delivery method. It is FDA-approved in IV form (Carnitor) for primary carnitine deficiency and dialysis patients. SC injectable use for fat oxidation enhancement is off-label but widely used in metabolic optimization clinics.
Key claims: Enhances fat oxidation during exercise; Improves exercise performance; Supports cardiovascular health.
Shared Research Applications
Both peptides are studied for: Body Composition.
CJC-1295 is also researched for: Anti-Aging.
L-Carnitine (Injectable) is also researched for: Metabolic Health.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
L-Carnitine (Injectable): Generally well tolerated; long safety record in approved IV formulations SC injection site pain/burning (common with higher concentrations) Rare: nausea, diarrhea, body odor (fishy smell at very high doses)
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Ipamorelin: Selective GH Secretagogue for Clean Pulsatile Release
Ipamorelin, a third-generation GHS-R1a agonist (CAS 170851-70-4), stimulates pulsatile growth hormone release without elevating cortisol or prolactin, unlike earlier GHRPs. This selectivity supports precise research into GH axis effects, IGF-1 pathways, body composition, recovery, and sleep. Studies highlight its role in anabolic processes and synergy with CJC-1295 for enhanced GH output.